Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B Cell Responses to Influenza Vaccine
NCT03748524Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2018
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of influenza vaccine in influenza, sponsored by Washington University School of Medicine. Primary endpoint: Percentage of subjects achieving seroconversion at Day 28. Started Oct 2018; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03748524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748524.